Population pharmacokinetics of serelaxin in patients with acute or chronic heart failure, hepatic or renal impairment, or portal hypertension and in healthy subjects

British Journal of Clinical Pharmacology
Antoine SoubretMarion Dahlke

Abstract

Serelaxin is a recombinant human relaxin-2 peptide being developed for the treatment of acute heart failure (AHF). The present analyses aimed to evaluate serelaxin pharmacokinetics following intravenous administration and to identify covariates that may explain pharmacokinetic variability in healthy subjects and patients. Serum concentration-time data for 613 subjects from nine phase I and II studies were analysed using a nonlinear mixed-effects model to estimate population pharmacokinetics and identify significant covariates. A quantile regression analysis was also conducted to assess the relationship between clearance and covariates by including sparse data from a phase III study. A three-compartment disposition model was established to describe serelaxin pharmacokinetics. Three out of 23 covariates, including baseline body mass index (BMI) and estimated glomerular filtration rate (eGFR) and study A1201, were identified as significant covariates for clearance but with a moderate impact on steady-state concentration, reducing the intersubject variability from 44% in the base model to 41% in the final model with covariates. The steady-state volume of distribution (Vss) was higher in patients with AHF (544 ml kg-1 ) or chronic h...Continue Reading

References

Jul 19, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Avraham ShotanSimcha Meisel
May 2, 2006·Pharmacology & Therapeutics·Thomas DschietzigKarl Stangl
Aug 4, 2009·The AAPS Journal·Radojka M Savic, Mats O Karlsson
Jan 28, 2010·Nature Reviews. Cardiology·Robert A Guyton
Jul 2, 2010·Survey of Ophthalmology·Ron Gutmark, David L Guyton
Nov 13, 2012·Lancet·John R TeerlinkUNKNOWN RELAXin in Acute Heart Failure (RELAX-AHF) Investigators
Dec 17, 2014·British Journal of Clinical Pharmacology·Zhanna KobalavaAtef Halabi
Apr 29, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Naoki SatoMasatoshi Kawana
Nov 26, 2015·Heart·Jeremy Tietjens, John R Teerlink
Nov 4, 2016·Pharmaceutical Research·Marc Lavielle, Benjamin Ribba
Oct 22, 2017·British Journal of Pharmacology·Stephen Ph AlexanderUNKNOWN CGTP Collaborators

❮ Previous
Next ❯

Citations

Apr 12, 2021·Molecular Therapy : the Journal of the American Society of Gene Therapy·Nuttarak SasipongPhilip W J Raake
Jun 9, 2021·Biochimie·Devaraj Ezhilarasan
Aug 5, 2021·American Journal of Physiology. Regulatory, Integrative and Comparative Physiology·Kirk P ConradMark S Segal

❮ Previous
Next ❯

Related Concepts

Related Feeds

Argentine Hemorrhagic Fever

Argentine hemorrhagic fever (AHF) is an endemo-epidemic disease caused by junín virus (JUNV), a member of the arenaviridae family. Discover the latest research on AHF here.